SCNI: Rega marang dodolan Scinai

In-house GMP manufacturing minimizes the need for contractors, which supports the price-to-sales multiple. The value 0.20 captures the magnitude of this parameter. The financial stability of Scinai Immunotherapeutics (SCNI) relies on grants and the success of nanobody testing. Patent protection for immunotherapy developments creates growth potential that will be realized upon the completion of clinical trials.
Rincian metrik lan analitis perusahaan Scinai Immunotherapeutics Ltd. (SCNI)

Scinai Immunotherapeutics focuses on developing innovative nano-antibodies to combat autoimmune pathologies and viral infections. By analyzing the current P/S ratio, an investor assesses the company's market value relative to its annual revenue, which helps identify whether the asset is overbought or if its commercial potential is undervalued against the backdrop of expected clinical trial results and the volume of secured grant funding.